An open-label multiyear study of sargramostim-treated Parkinson's disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers.

ABSTRACT:

Background

The clinical utility and safety of sargramostim has previously been reported in cancer, acute radiation syndrome, autoimmune disease, inflammatory conditions, and Alzheimer's disease. The safety, tolerability, and mechanisms of action in Parkinson's disease (PD) during extended use has not been evaluated.

Methods

As a primary goal, safety and tolerability was assessed in five PD patients treated with sargramostim (Leukine^®, granulocyte-macrophage colony-stimulating factor) for 33 months. Secondary goals included numbers of CD4⁺ T cells and monocytes and motor functions. Hematologic, metabolic, immune, and neurological evaluations were assessed during a 5-day on, 2-day off therapeutic regimen given at 3 μg/kg. After 2 years, drug use was disco

SUBMITTER: Olson KE 

PROVIDER: S-EPMC10201023 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature